Compare SIBN & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIBN | VALN |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | France |
| Employees | 349 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.4M | 820.0M |
| IPO Year | 2018 | 2021 |
| Metric | SIBN | VALN |
|---|---|---|
| Price | $20.36 | $8.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $25.57 | $15.75 |
| AVG Volume (30 Days) | ★ 486.6K | 24.4K |
| Earning Date | 11-10-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $193,578,000.00 | ★ $211,089,992.00 |
| Revenue This Year | $21.44 | $5.08 |
| Revenue Next Year | $15.30 | $12.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.27 | 13.48 |
| 52 Week Low | $12.50 | $4.02 |
| 52 Week High | $21.07 | $12.25 |
| Indicator | SIBN | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 63.98 | 45.38 |
| Support Level | $18.34 | $8.26 |
| Resistance Level | $21.07 | $8.64 |
| Average True Range (ATR) | 0.73 | 0.28 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 73.99 | 40.09 |
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.